Redefining Value in Obesity Drug Development: A Focus on the Full Cardiometabolic Continuum
GLP-1 receptor agonists have fundamentally changed the diabetes and obesity treatment landscape and are now demonstrating outcomes in multiple cardiovascular, kidney and metabolic diseases. The next phase of obesity drug development will not be won by marginal differences in mean population weight loss. It will be won by assets that demonstrate credible modification of the biologic drivers of disease risk.
In this perspective piece, Syneos Health experts explore obesity’s evolution from a therapeutic endpoint to a therapeutic gateway. It takes a close look at how this evolution opens new worlds of opportunity for sponsors who can rise to the challenges of adopting a pathway-centric development strategy defined by shifts in early phase planning, biomarker development, innovative study design, decentralization and endpoint evolution.
Winning in obesity-drug development will depend on the ability to manage the complexity of multiple, interconnected conditions and to make deliberate choices that reflect the realities of science, care delivery and patient journeys—in other words, on the ability to design for the full cardiometabolic reality.
